Poseida Therapeutics Inc PSTX

Healthcare Biotechnology

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

NDAQ:PSTX - Post by User

Poseida Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by ProfitGrid8448on Nov 26, 2024 8:21am

7 Views

Post# 36330740

Roche Acquires $PSTX in $1.5B Deal, Eyes on $MYNZ

Big news for $PSTX—Roche is acquiring the company in a $1.5B deal, valuing shares at nearly $9 each. A solid premium for investors. With its cutting-edge test developments, $MYNZ could be another candidate for acquisition in the sector. Watching both closely.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China